MétaCan
Menu
Back to cohort
Record W4389480683 · doi:10.1016/j.iotech.2023.100693

LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study

2023· article· en· W4389480683 on OpenAlexaff
Solange Peters, Byoung Chul Cho, Alexander Luft, J.A. Alatorre Alexander, Sarayut Lucien Geater, К. К. Лактионов, Dmytro Trukhin, Seung‐Whan Kim, G. Ursol, Maen Hussein, F. Lim, Cheng‐Ta Yang, L.H. Araujo, H. Saito, Niels Reinmuth, Leah Szadkowski, C. Lowery, Edward B. Garon, Tony Mok, Melissa L. Johnson

Bibliographic record

VenueImmuno-Oncology Technology · 2023
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsAstraZeneca (Canada)
FundersAstraZeneca
KeywordsMedicineInternal medicineDurvalumabRegimenChemotherapyGastroenterologyProgression-free survivalNuclear medicineConfidence intervalOncologyImmunotherapyPembrolizumabCancer

Abstract

fetched live from OpenAlex

In the phase 3 POSEIDON study, 1L T+D+CT demonstrated statistically significant improvements in both progression-free survival (PFS) and OS (HR 0.77; 95% CI 0.65‒0.92; p=0.0030; median follow-up [FU] 34.9 mo in censored patients [pts] across all three arms) vs CT alone in pts with EGFR/ALK wild-type mNSCLC, leading to approvals for this regimen. D+CT significantly improved PFS vs CT, with a trend for OS improvement that did not reach statistical significance (HR 0.86; 95% CI 0.72‒1.02; p=0.0758). Here we report long-term OS results after median FU of >5 y. Pts (n=1013) were randomised 1:1:1 to 1L treatment with: D (until progression) ± limited-course T (up to 5 doses) + platinum-based CT (up to 4 cycles); or CT (up to 6 cycles). Stratification factors were tumour cell (TC) PD-L1 expression (TC ≥50% vs <50%; VENTANA PD-L1 [SP263] assay), disease stage (IVA vs IVB) and histology (squamous vs NSQ). Long-term FU analysis of OS was prespecified. Serious AEs were collected during long-term FU. T+D+CT showed sustained OS benefit vs CT (HR 0.76; 95% CI 0.64–0.89) at an updated data cutoff of 24 Aug 2023 (median FU 63.4 mo in censored pts), with 5-y OS rates of 15.7% vs 6.8% (Table). OS improvement with D+CT vs CT remained lower in magnitude (HR 0.84; 95% CI 0.72–1.00; 5-y OS 13.0%). Updated results suggested that OS benefit with T+D+CT vs CT continued to be more pronounced in pts with NSQ vs squamous histology (data will be presented). Consistent with earlier analyses, OS benefit was maintained with T+D+CT (but not D+CT) vs CT in pts with PD-L1 TC <1%. OS by STK11/KEAP1/KRAS mutation status will be presented. No new safety signals were identified.Table: LBA3T+D+CTD+CTCTITT, n mOS (95% CI), mo HR vs CT (95% CI)* 5-y OS (95% CI), %338 14.0 (11.7–16.1) 0.76 (0.64–0.89) 15.7 (12.0–19.9)338 13.3 (11.4–14.7) 0.84 (0.72–1.00) 13.0 (9.6–16.9)337 11.6 (10.5–13.1) – 6.8 (4.4–10.0)NSQ, n mOS (95% CI), mo HR vs CT (95% CI)† 5-y OS (95% CI), %214 17.2 (14.9–21.8) 0.69 (0.56–0.85) 20.5 (15.3–26.2)209 14.8 (11.8–18.3) 0.81 (0.66–1.00) 16.4 (11.6–21.8)214 13.0 (10.6–15.1) – 9.1 (5.6–13.6)PD-L1 TC <1%, n mOS (95% CI), mo HR vs CT (95% CI)† 5-y OS (95% CI), %125 12.7 (9.9–15.5) 0.81 (0.62–1.05) 6.1 (2.6–11.8)113 10.9 (8.1–13.5) 0.98 (0.75–1.27) 6.5 (2.9–12.2)130 11.0 (8.7–12.7) – 4.0 (1.5–8.6)*Stratified/†unstratified analysis. mOS, median OS; NSQ, non-squamous. Open table in a new tab *Stratified/†unstratified analysis. mOS, median OS; NSQ, non-squamous. Updated analyses from POSEIDON after median FU of >5 y showed durable long-term OS benefit with the approved regimen of T+D+CT (vs CT alone). These results support its use as a 1L treatment option for pts with mNSCLC, including harder-to-treat subgroups such as those with PD-L1 TC <1%.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.513
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.002
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.314
Teacher spread0.289 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueImmuno-Oncology TechnologySame topicCancer Immunotherapy and BiomarkersFrench-language works237,207